• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Brainstem ganglioglioma successfully treated with vemurafenib.

作者信息

Rush Sarah, Foreman Nicholas, Liu Arthur

机构信息

University of Colorado Denver, Denver, CO, USA.

出版信息

J Clin Oncol. 2013 Apr 1;31(10):e159-60. doi: 10.1200/JCO.2012.44.1568. Epub 2013 Jan 28.

DOI:10.1200/JCO.2012.44.1568
PMID:23358987
Abstract
摘要

相似文献

1
Brainstem ganglioglioma successfully treated with vemurafenib.用维莫非尼成功治疗脑干节细胞胶质瘤。
J Clin Oncol. 2013 Apr 1;31(10):e159-60. doi: 10.1200/JCO.2012.44.1568. Epub 2013 Jan 28.
2
Successful Retreatment of a Child with a Refractory Brainstem Ganglioglioma with Vemurafenib.用维莫非尼成功复治一名难治性脑干神经节胶质瘤患儿。
Pediatr Blood Cancer. 2016 Mar;63(3):541-3. doi: 10.1002/pbc.25787. Epub 2015 Nov 18.
3
Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas.维莫非尼治疗 BRAFV600E 突变型高级别胶质瘤的儿科患者。
Pediatr Blood Cancer. 2014 Jun;61(6):1101-3. doi: 10.1002/pbc.24891. Epub 2013 Dec 3.
4
Vemurafenib for melanoma metastases to the brain.维莫非尼用于治疗黑色素瘤脑转移。
N Engl J Med. 2011 Dec 22;365(25):2439-41. doi: 10.1056/NEJMc1111672.
5
Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.复发性BRAFV600E突变型神经节胶质瘤对维莫非尼单药治疗的反应
J Transl Med. 2014 Dec 19;12:356. doi: 10.1186/s12967-014-0356-1.
6
Vemurafenib and cobimetinib overcome resistance to vemurafenib in -mutant ganglioglioma.维莫非尼和考比替尼克服了BRAF V600E突变型神经节胶质瘤对维莫非尼的耐药性。
Neurology. 2018 Sep 11;91(11):523-525. doi: 10.1212/WNL.0000000000006171. Epub 2018 Aug 17.
7
Multimodal magnetic resonance imaging and 18F-L-dihydroxyphenylalanine positron emission tomography in early characterization of pseudoresponse and nonenhancing tumor progression in a pediatric patient with malignant transformation of ganglioglioma treated with bevacizumab.多模态磁共振成像和18F-L-二羟基苯丙氨酸正电子发射断层扫描在贝伐单抗治疗的神经节胶质瘤恶变小儿患者假性反应和无强化肿瘤进展早期特征分析中的应用
J Clin Oncol. 2013 Jan 1;31(1):e1-5. doi: 10.1200/JCO.2012.43.6113. Epub 2012 Nov 19.
8
Pilomyxoid astrocytoma treated successfully with vemurafenib.维莫非尼成功治疗毛黏液样星形细胞瘤。
Pediatr Blood Cancer. 2014 Nov;61(11):2099-100. doi: 10.1002/pbc.25084. Epub 2014 May 12.
9
[Progress of research and development of MAPK pathway inhibitors].[丝裂原活化蛋白激酶（MAPK）信号通路抑制剂的研发进展]
Nihon Yakurigaku Zasshi. 2013 Jan;141(1):15-21. doi: 10.1254/fpj.141.15.
10
Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan.BRAF 突变型胆管癌对维莫非尼、帕尼单抗和伊立替康的完全临床缓解
J Gastrointest Cancer. 2016 Dec;47(4):502-505. doi: 10.1007/s12029-015-9792-2.

引用本文的文献

1
VOPP1::EGFR fusion is associated with NFκB pathway activation in a glioneural tumor with histological features of ganglioglioma.在具有节细胞胶质瘤组织学特征的神经胶质瘤中，VOPP1::表皮生长因子受体（EGFR）融合与核因子κB（NFκB）信号通路激活相关。
Acta Neuropathol Commun. 2025 Apr 16;13(1):76. doi: 10.1186/s40478-025-01994-1.
2
BRAF V600E Mutation in Ganglioglioma: Impact on Epileptogenicity and Implications for Surgical Strategy.神经节细胞胶质瘤中的BRAF V600E突变：对致痫性的影响及手术策略的意义
Eur J Neurol. 2025 Apr;32(4):e70136. doi: 10.1111/ene.70136.
3
Three Years of Progression-free after Biopsy of BRAF V600E-negative Ganglioglioma in the Adult Brainstem: A Case Report and the Literature Review.
成人脑干BRAF V600E阴性神经节胶质瘤活检后三年无进展：一例报告及文献综述
NMC Case Rep J. 2024 Dec 25;11:427-433. doi: 10.2176/jns-nmc.2024-0189. eCollection 2024.
4
Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G.BRAF V600 突变肿瘤患儿和青年患者中 vemurafenib 的 II 期研究：NCI-COG 儿科 MATCH 试验（APEC1621）G 臂
Oncologist. 2024 Aug 5;29(8):723-e1093. doi: 10.1093/oncolo/oyae119.
5
BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.BRAF-MEK 抑制在新诊断的颅咽管瘤中的应用。
N Engl J Med. 2023 Jul 13;389(2):118-126. doi: 10.1056/NEJMoa2213329.
6
Unlocking the power of precision medicine for pediatric low-grade gliomas: molecular characterization for targeted therapies with enhanced safety and efficacy.释放精准医学对儿童低级别胶质瘤的力量：用于具有更高安全性和疗效的靶向治疗的分子特征分析
Front Oncol. 2023 Jun 15;13:1204829. doi: 10.3389/fonc.2023.1204829. eCollection 2023.
7
Response and resistance to BRAF inhibition in gliomas: Roadblocks ahead?胶质瘤对BRAF抑制的反应与耐药性：前方的阻碍？
Front Oncol. 2023 Jan 9;12:1074726. doi: 10.3389/fonc.2022.1074726. eCollection 2022.
8
Early molecular diagnosis of BRAF status drives the neurosurgical management in BRAF V600E-mutant pediatric low-grade gliomas: a case report.BRAF V600E 突变型儿童低级别胶质瘤的 BRAF 状态早期分子诊断指导神经外科治疗：病例报告。
BMC Pediatr. 2022 Nov 29;22(1):685. doi: 10.1186/s12887-022-03711-6.
9
Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric V600-Mutant Low-Grade Glioma.曲美替尼单药或联合达拉非尼治疗儿童 V600 突变型低级别胶质瘤的疗效和安全性。
J Clin Oncol. 2023 Jan 20;41(3):664-674. doi: 10.1200/JCO.22.01000. Epub 2022 Nov 14.
10
Adult pilocytic astrocytoma in the molecular era: a comprehensive review.成人毛细胞型星形细胞瘤的分子时代：全面综述。
CNS Oncol. 2021 Mar 1;10(1):CNS68. doi: 10.2217/cns-2020-0027. Epub 2021 Jan 15.